A smart way to manage diabetes in pregnancy.

Easily connect state-of-the-art diabetes management into your obstetrics practice.

"LilyLink is changing the game by empowering OBGYNS and their patients with synchronous, easily-digestible data to drive better care and improve outcomes."

Audrey Merriam
MD, OBGYN, Maternal-Fetal Medicine
Created with expert advisors from

1 in 7 pregnancies are complicated by diabetes.

Diabetes increases risks and is time-intensive to manage for both patients and providers.

Pregnant women have been an afterthought for diabetes tech companies.

Gestational diabetes is different from other types — there is no one-size-fits-all approach.

LilyLink is closing the gap.

Equip your OB clinic with the first billable, tech-enabled diabetes platform built specifically for high-risk prenatal care.

Improve patient experience and outcomes.
Streamline diabetes management work and reduce staff burnout.
Track and claim remote monitoring activities.

An end-to-end platform developed by a team of OBGYN, MFM, and RD providers

Automate postprandial logging with patient mobile app
View data summaries directly from an EHR-integrated portal
Easily implement CGMs as part of standard of care
Increase reimbursements with remote monitoring tools
Leverage a virtual team for diabetes training and nutrition counseling

An end-to-end platform developed by and for clinical providers.

Automate postprandial logging with patient mobile app

A simple, intuitive app with one-tap meal entry, weekly glucose summaries, and apple health integration.

View data summaries from an EHR-integrated portal

Aggregate patient data and access quick summaries to help streamline patient care and stratify risk.

Easily implement CGMs as part of standard of care

Our platform transforms raw continuous glucose monitoring (CGM) data into actionable postprandial logs recommended by the latest clinical guidelines.

Increase reimbursements with remote monitoring tools

Track RPM activities and increase reimbursements through new billings.

A virtual team for diabetes training & nutrition counseling

Our GDM-trained dietician and certified diabetes educators serve as an extension of your clinic staff.

Compatible with leading glucose monitoring devices
Check out our blog

Stay up-to-date with the latest developments in GDM care.

Featured

April 14, 2025

Transforming Gestational Diabetes Management with Continuous Glucose Monitoring

Wearing a CGM can alleviate some of the burdens associated with managing diabetes, while simultaneously enabling healthcare providers to make more informed and timely treatment decisions. Although the use of CGMs in pregnancy—particularly for gestational diabetes—has been underutilized, there is growing momentum behind its application. 

CGMs have been used with great success in people with type 1 and type 2 diabetes, so why aren’t they more widely used in pregnancy? One reason is that the research on CGM use in pregnancy pales in comparison to the other types of diabetes. A robust body of data is required to inform American College of Obstetrics and Gynecology (ACOG) guidelines, therefore leaving us wanting for solid recommendations. 

Although there aren't set guidelines for CGM use in gestational diabetes, early research shows the benefits of incorporating the technology in prenatal care. In this post, we’ll explore the proven benefits of CGM technology in pregnancy and how you can effectively integrate it into your clinical practice.

Lower Average Blood Glucose and Reduce Maternal Weight Gain

Managing gestational diabetes is all about achieving blood glucose levels that reduce maternal and infant complications. A 2022 meta-analysis by Garcia-Mareno et al found that patients with gestational diabetes (GDM) who used CGM achieved lower average blood glucose levels and lower maternal weight gain and infant birth weight than those using conventional finger-stick blood glucose monitoring (SMBG).1 

Similar results were found in a recent trial comparing real-time CGM (rt-CGM) with the use of SMBG for the management of GDM.2 CGM users spent significantly more time in range (60-140 mg/dL) than those doing fingersticks.

Likewise, the Flash Glucose Monitoring in Gestational Diabetes Mellitus (FLAMINGO) randomized control trial revealed the positive impact of CGM on glucose levels.3 While mean glucose between the control (SMBG) and intermittently-scanned CGM groups wasn’t significant, the CGM group significantly reduced fasting and postprandial glucose levels during the first 4 weeks following GDM diagnosis.

Lowering the mean glucose levels in pregnancy has multiple benefits for the baby, and simply replacing fingersticks with CGM technology may make it easier to achieve.

Detect High-Risk Patients

Even short-term (14-day) CGM use can help identify patients with a higher risk profile. In a prospective cohort study by Liang et al, CGM-derived data correlated with pregnancy outcomes.4 A higher number of values above the target range per sensor data was associated with greater NICU admissions. The research team found that CGM use for 14 days could be used to design interventions for high-risk pregnancies to improve health status among patients with gestational diabetes.

Potential Alternative to Oral Glucose Tolerance Test

Many patients dread the oral glucose tolerance test (OGTT). While it seems simple enough—consume glucose and draw labs—the patient experience is not always ideal. Emerging research is supporting the use of CGM as a viable alternative. Researchers surveyed pregnant patients to evaluate the acceptability of the OGTT vs. CGM to diagnose GDM.5 CGM use was preferred by 81% of polled participants, and 93% of participants recommended it for GDM diagnosis. 

One major upside to CGM diagnostic use is that it directly measures the high blood sugars in a real-world scenario, which the OGTT is supposed to predict.

Overall, the research implies that CGM use in gestational diabetes is advantageous.  The technology has the potential to improve monitoring, care, and outcomes while enhancing the patient experience.  However, more conclusive data is needed to change existing guidelines. To that end, multiple research projects are underway to further study the benefits of CGM use in pregnancy.

Current Clinical Trials Involving CGM Use in Gestational Diabetes

The demand for validation of CGM use in GDM is evident. Fortunately, there are many research teams currently studying the technology. Some clinical trials that are underway include:

Making CGMs Work for Your Obstetrics Practice

Using CGM technology to support pregnancies complicated by diabetes has many potential benefits. There’s the potential to reduce glucose levels and maternal weight gain, lower the risk of macrosomia, and better inform behavior modification. 

While the potential benefits are there, ACOG guidelines for monitoring and treatment continue to be based around fasting and postprandial glucose values.  These guidelines have been built up through decades of research, and changing them will take time and more rigorous research.

That said, there are ways to make CGMs compatible with ACOG guidelines by calculating fasting and postprandial glucose directly from the CGM data.  With a connected app like LilyLink, patients just need to enter their meal and wakeup times and this data can be extracted.  Apps can also make it easy for providers to view patient data through a centralized dashboard.

It’s critical any app for pregnancy sets the proper recommended glucose ranges, which differs from Type 1 and 2. 

Book a demo to see how we can collaborate to deliver cutting-edge, data-driven solutions that will transform the future of prenatal care.

  1. García-Moreno RM, Benítez-Valderrama P, Barquiel B, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022;39(1):e14703. doi:10.1111/dme.14703
  2. Valent AM, Huertas-Pagan C, Ward L, Rickert MC, Rincon M. 259-OR: Real-time CGM achieves higher TIR among pregnant persons with GDM. Diabetes. 2024;73(Supplement_1):259–OR. doi:10.2337/db24-259-OR.
  3. Majewska A, Stanirowski PJ, Tatur J, et al. Flash glucose monitoring in gestational diabetes mellitus (FLAMINGO): a randomised controlled trial [published correction appears in Acta Diabetol. 2023 Oct;60(10):1439. doi: 10.1007/s00592-023-02159-z]. Acta Diabetol. 2023;60(9):1171-1177. doi:10.1007/s00592-023-02091-2
  4. Liang X, Fu Y, Lu S, et al. Continuous glucose monitoring-derived glycemic metrics and adverse pregnancy outcomes among women with gestational diabetes: a prospective cohort study. Lancet Reg Health West Pac. 2023;39:100823. Published 2023 Jun 12. doi:10.1016/j.lanwpc.2023.100823
  5. Di Filippo D, Darling J, Chang MHY, Henry A, Welsh A. Oral glucose tolerance test and continuous glucose monitoring for gestational diabetes diagnosis: a survey study of women and health care professionals. Arch Gynecol Obstet. 2024 Feb;309(2):483-489. doi: 10.1007/s00404-023-06949-2.

Hear what practitioners and patients are saying

"LilyLink's CGM integration is uniquely designed to support diabetes during pregnancy — I’m excited about enhancing my own care through improved data collection and data-driven insights."

Jill Garnier
MD, OBGYN, FACOG

“LilyLink takes diabetes management during pregnancy to the next level for providers and patients. Being able to gather and interpret data in one place, and be reimbursed for it, will improve the way we provide care!”

Christina Inteso
PharmD, CDCES

"Managing gestational diabetes can be overwhelming for patients. LilyLink streamlines the process, offering valuable feedback and support which empowers patients to manage their condition more effectively."

Erin Davis
RD, CDCES

"It gives me peace of mind knowing that the data is automatically transferred and synced, which means there aren’t gaps when patients weren’t able to update their log"

Hebron Kelecha
MD, MPH

I love this app! It’s so much easier, I don’t have to step out of meetings to check blood sugars anymore. I just take a picture when I eat and the data that comes out is exactly what my OB wants.”

Erin Sweeney
GDM patient